Materials and Methods: 33 NPC patients, received IMRT concurrently with four to six cycles of cisplatin (30 mg / m2 / day) every six weeks between May 2016 and July 2018, were evaluated prospectively. The doses to the planning target volumes of primary tumor and involved lymph nodes, uninvolved regional nodal areas were 70 Gy and 50 Gy respectively.